Maintenance Treatment of Renal Anemia in Dialysis Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 229 participants.

Also called NCT03543657

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 229 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03543657
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03543657. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-23 (actual); primary completion 2019-08-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Maintenance Treatment of Renal Anemia in Dialysis Subjects
Acronym
MIYABI HD-M
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Molidustat (BAY85-3934)
Intervention (Drug)
Darbepoetin alfa
Intervention (Drug)
Placebo of Molidustat (BAY85-3934)
Intervention (Drug)
Placebo of Darbepoetin alfa
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03543657
Content hash
4645898407eebcd36d9e5b444180cc0722390255057b4e8f69cacd6ae7a1e9fc